Welcome

to the center of excellence for hematology and oncology at the Hirslanden Clinic in Zurich

Our clinic provides comprehensive treatment and care for both out-patients and in-patients with blood diseases and malignant tumours. Our team of oncologists and other specialists collaborate to ensure continuity of care as well as a high level of treatment. We offer modern immunotherapies as well as cell therapies (CAR T therapies) for a wide range of diseases.

Our team of experts is highly committed to our patients’ well-being.

We will support you on your personal journey, providing the highest professional standards in a personal and caring atmosphere, all under the one roof.

The Clinic for Haematology & Oncology Hirslanden Zurich is part of the tumour centre at the Hirslanden Clinic and is certified according to the guidelines of the Swiss Cancer Network.

Latest news

Cancer Research | From Theory to Therapy

Living with Cancer - The Podcast

Before a new drug is approved, it is tested on humans in clinical trials. These studies represent a central step in cancer research. Patients are directly involved: through their participation, they contribute crucially to the development of new therapies and thereby offer hope for future sufferers.

We speak with PD Dr. med. Karin Hohloch from the Hirslanden Clinic Zurich about the significance of clinical research, how it is implemented at their Tumor Center, and why it is indispensable for medical progress.

To the podcast

Rectal Cancer: A New Treatment Approach Offers Hope

A year after his diagnosis of rectal cancer, Ivan is cancer-free. Almost at the same time as his diagnosis, a U.S. study was published that described a new treatment approach for his form of cancer. This changes everything for Ivan—for the better.

Find the full article here.

CARVYKTI NEW AT THE KLINIK HIRSLANDEN

Since June 2025, Klinik Hirslanden in Zurich has been offering an additional CAR T-cell product, CARVYKTI, for the treatment of multiple myeloma (bone marrow cancer). This new therapy complements the CAR T-cell treatments already established at our clinic since late 2019, which have been successfully used to treat both bone marrow cancer and lymphoma.

This advanced immunotherapy is intended for patients with multiple myeloma who no longer respond adequately to other cancer treatments. Switzerland is among the first five countries worldwide where CARVYKTI is available. Within Switzerland, Klinik Hirslanden Zurich is one of the few specialized centers offering this highly advanced therapy.

CAR T-cell therapy is based on the genetic modification of the patient’s own T cells – white blood cells that play a central role in the immune system.

With CARVYKTI, the collected T cells are equipped with a so-called chimeric antigen receptor (CAR), which specifically targets the B-cell maturation antigen (BCMA) – a protein mainly found on malignant plasma cells. After reinfusion into the body, these modified cells can specifically recognize and destroy the cancer cells, which had previously gone undetected by the natural immune system.

You can find more information about CAR T-cell therapy at Klinik Hirslanden Zurich hier.

For questions regarding CAR T-cell therapy or the referral of suitable patients, Prof. Dr. med. Christoph Renner, Director of the Medical Cell Therapy Program at Klinik Hirslanden in Zurich, is available at +41 44 387 37 80.

Blood cancer disease caused by altered plasma cells in the bone marrow

GESUNDHEIT HEUTE interview with Prof. Christoph Renner and his long-time patient Ms. Désirée Bernal